Applications extend beyond oncology, as cyclodextrin-based nanoparticles have also been engineered for siRNA delivery in neurodegenerative disorders, including Huntington’s disease, where β-cyclodextrin derivatives facilitated neuronal uptake and silencing of mutant huntingtin expression in cellular and animal models [128]. This evidence concerns the gene HTT and Huntington disease.